HM15136
Phase 2Small molecule
Hanmi Pharmaceutical Company LimitedHM15136 is one of 10 small molecule programs targeting Hyperinsulinism. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Hyperinsulinism
#DrugCompanyPhaseTrials
1Lanreotide PRF
IpsenApproved
Zegalogue
Zealand PharmaPhase 3
Glucagon
XXeris Pharmaceuticals
Phase 2
Exendin-(9-39)
EEiger BioPharmaceuticals
Phase 2
Ersodetug
RRezolute
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 1
Fluorodopa F 18
MMayo Clinic
Phase 1
HM15136
Hanmi Pharmaceutical Company LimitedPhase 2
Insulin-Like Growth Factor I
CChildren's Hospital of Philadelphia
Preclinical
Glucagon-Like Peptide-1 (GLP-1)
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HM15136. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details